Table 1 Baseline characteristics of patients of proliferative lupus nephritis
III | IV | III/IV+V | |
|---|---|---|---|
Number | 44 | 35 | 50 |
Age, years, mean ± SD | 45.7 (15.3) | 40.0 (14.1) | 41.1 (11.6) |
Sex, female, n (%) | 41 (93.2) | 32 (91.4) | 40 (80.0) |
BMI, mean ± SD | 22.0 (3.5) | 21.8 (4.0) | 21.5 (3.8) |
Duration of SLE, years, mean ± SD | 10.9 (9.7) | 10.5 (7.9) | 12.1 (6.6) |
Systolic BP, mmHg, mean ± SD | 128.0 (18.0) | 137.7 (25.7) | 128.3 (24.0) |
Serum creatinine, mg/dL, mean ± SD | 0.8 (0.3) | 0.9 (0.5) | 1.0 (0.6) |
Antiphospholipid antibody, n (%) | 18 (40.9) | 12 (34.3) | 12 (24.0) |
eGFR, mL/min/1.73 m2, mean ± SD | 79.5 (24.3) | 66.7 (27.0) | 82.9 (32.6) |
Urinary protein, g/g, mean ± SD | 1.2 (1.3) | 3.2 (2.4) | 3.0 (3.1) |
Nephrotic syndrome, n (%) | 8 (18.2) | 23 (65.7) | 25 (50.0) |
RPGN, n (%) | 4 (9.1) | 9 (25.7) | 3 (6.0) |
Activity and chronicity assessment | |||
ISN/RPS 2003 classification, n (%) | |||
A | 18 (40.9) | 8 (22.9) | 7 (14.0) |
A/C | 20 (45.5) | 22 (62.9) | 28 (56.0) |
C | 6 (13.6) | 5 (14.3) | 15 (30.0) |
2018 mNIH index, median (IQR) | |||
Activity index | 3 (2, 5) | 8 (1, 6) | 3 (1, 6) |
Chronicity index | 2 (2, 4) | 3 (2, 5) | 3 (2, 4) |
Treatment | |||
Initial dosage of PSL, mean ± SD | 39.3 (15.5) | 42.8 (15.5) | 38.3 (15.5) |
CYC or MMF, n (%) | 8 (18.2) | 16 (45.7) | 8 (16.0) |
Other immunosuppressants, n (%) | 11 (25.0) | 15 (42.9) | 14 (28.0) |
RAS inhibitor, n (%) | 14 (31.8) | 15 (42.9) | 16 (32.0) |